Clear Search

Showing 2 results for “discontinuation”.

November 2025

Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: A case series in China

Lancet 2025 Doi:10.1016/S0140-6736(25)01671-X Epub ahead of print

Gao et al. report that allogeneic CAR NK-cell therapy is a potent option for treatment of autoimmune diseases and may address limitations of current autologous CAR T-cell therapy, including manufacturing scale and time, access, safety, and cost. Authors evaluated the safety, tolerability, and efficacy of allogeneic CD19 CAR NK-cell therapy in patients with relapsed or refractory SLE.

more…

August 2024

Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes

Rheumatol 2024 DOI 10.1093/rheumatology/keae381 Epub ahead of print

This study by Panagiotopoulos, et al. showed that an early complete renal response achievement, persistent hydroxychloroquine use, and the maintenance of optimal low disease activity during follow-up in immunosuppressive (IS) tapering and discontinuation are fundamental in LN treatment. The authors also found that long-term renal outcomes are mainly associated with renal flares during IS tapering.

more…